ABIVAX SA

Abivax’s stock may rise, but analysts’ optimism masks over‑valuation and a loss‑making pipeline—investors face high risk, low liquidity and uncertain upside.

Abivax shares rise modestly as analysts lift buy ratings, spotlighting its vaccine pipeline for HIV, hepatitis B and emerging infections.

Abivax shares dip 1.27% at €83.25 amid sector‑wide volatility—yet the biotech firm’s robust vaccine pipeline and strong 200‑day trend hint at future upside.